NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

biosectinvestor,

Remember that L is limited by the number of antigens in just the tumor removed and needs help often times to control any remaining tumor which is made more difficult by unmethylated status microenvironment and micro metastis. Direct can be injected in multiple tumors but this wasn’t done in Phase 1. It also modifies the tumor environment by signaling which must remain constant/continuous to be the most effective. This can happen one of at least two ways. Proper interval between treatments or sufficient initial immune response that creates a steady influx of new uncompromised DCs from the patients own production of them which then continue to control the tumor environment by activation and maturation there. Every patient situation is different which is why treatment needs to be personalized but also consistent and continuous with proper spacing which treatment induced pseudo progression and trial protocols for first in man designation prevented in the Phase 1.
By the way, our grapefruit juice guy has become mighty quiet recently but the noise on the boards has increased. Seems like an inverse correlation to certain success has formed; ). Best wishes.